Reimagining cancer therapy

Pioneering precision
cancer therapies through
EDV™ nanocell technology

EnGeneIC is advancing a novel class of cancer therapies built on its proprietary EnGeneIC Dream Vector (EDV™) platform. By combining targeted delivery with immune activation, EDVs™ are designed to address one of the greatest challenges in cancer treatment: delivering potent therapies directly to tumours while minimising exposure to healthy tissue.

A longstanding challenge in cancer treatment

Despite advances in oncology, it is still difficult to deliver therapies precisely to tumours while limiting effects on healthy tissue.

Treatment burden and therapeutic resistance continue to drive the need for new approaches.

EnGeneIC was founded on the belief that improving the way therapies are delivered could transform cancer treatment.

Advancing multiple oncology programs

The EDV™ platform is in clinical trials in cancers with significant unmet medical need.

  • 01

    Pancreatic cancer

    Phase I/IIa

    In pancreatic cancer, EDVs™ are being evaluated alongside standard chemotherapy, addressing one of the hardest solid tumours to treat.

  • 02

    Recurrent glioblastoma

    Phase I/IIa

    In recurrent glioblastoma, EDVs™ are designed to deliver chemotherapy to brain tumours, addressing an area with few advances in treatment.

  • 03

    Mesothelioma

    Phase I/IIa (planned)

    In EGFR-expressing mesothelioma, EDVs™ will be evaluated for patients where treatment options remain poor.

Our pipeline

Latest news

Clinical, scientific and corporate updates from EnGeneIC.

More news